Neil Kumar, Ph.D., is the Chief Executive Officer at BridgeBio Pharma Inc., a biopharmaceutical company focused on developing transformative medicines for genetic diseases and cancers. Dr. Kumar holds a Ph.D. in chemistry from Stanford University, where he conducted groundbreaking research in the field of chemical biology. His academic journey laid a strong foundation for his career in the pharmaceutical industry, equipping him with the knowledge and skills to lead innovative drug development efforts. Prior to founding BridgeBio Pharma in 2015, Dr. Kumar gained valuable experience in the biotech sector, working at various prestigious organizations. He served as a consultant at McKinsey & Company, where he advised pharmaceutical and biotech companies on strategy and operations. Additionally, he worked at Third Rock Ventures, a leading healthcare venture capital firm, where he played a key role in identifying and nurturing promising early-stage biotech companies. These experiences provided him with a deep understanding of the industry and the challenges and opportunities in drug development. As the CEO of BridgeBio Pharma, Dr. Kumar has been instrumental in driving the company's mission to bridge the gap between scientific discovery and patient impact. Under his leadership, BridgeBio has grown rapidly, building a diverse portfolio of drug candidates targeting various genetic diseases and cancers. Dr. Kumar's visionary approach and commitment to scientific excellence have attracted top talent to the company and fostered strategic partnerships with leading academic institutions and pharmaceutical companies. His leadership has been pivotal in advancing BridgeBio's pipeline and bringing potentially life-changing therapies to patients in need.